Aytu BioPharmaAYTU -0.91%40 OCF Margin % is -33.70% as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Aytu BioPharma ranks worse than 66.32% on this metric.
The historical rank and industry rank for Aytu BioPharma's OCF Margin % or its related term are showing as below:
AYTU'
s OCF Margin % Range Over the Past 10 Years
Min: -435.52 Med: -71.13 Max: -2.13
Current: 2.96
During the past 13 years, the highest OCF Margin % of Aytu BioPharma was -2.13%. The lowest was -435.52%. And the median was -71.13%.
AYTU's OCF Margin % is ranked worse than 66.32% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs AYTU: 2.96
Aytu BioPharma OCF Margin % Related Terms
Aytu BioPharma OCF Margin % Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a OCF Margin % of -33.70% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Aytu BioPharma and its competitors. According to the industry distribution chart, Aytu BioPharma ranks #636 out of 959 companies in the Drug Manufacturers industry, placing it in the top 66.3%.
Is Aytu BioPharma's OCF Margin % too high?
Aytu BioPharma's current OCF Margin % is -33.70%. Based on the distribution chart, Aytu BioPharma ranks #636 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's OCF Margin % compare to TXMD and KAYS?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #636 out of 959 companies for OCF Margin %. This places Aytu BioPharma in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current OCF Margin % is -33.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.21 — trading 163.1% above its estimated fair value. The current OCF Margin % is -33.70%. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current OCF Margin % is -33.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.21 is trading 163.1% above its estimated GF Value™ of $0.84.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
OCF Margin %: -33.70%
GF Value™: $0.84 vs. price of $2.21 (163.1% above fair value)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for AYTU
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
